Eduard Torrents Serra

Eduard Torrents Serra serves as Group Leader of the Bacterial Infections: Antimicrobial Therapies research group at the Institute for Bioengineering of Catalonia (IBEC), where he has established himself as a leading researcher in microbial pathogenesis and novel antimicrobial strategies since joining in 2007. His career spans academic and industrial research environments across multiple countries.

His academic background includes:

• PhD in Microbiology (2001) from University Autonomous of Barcelona
• Postdoctoral research at Karolinska Institute under Prof. Peter Reichard
• Research position at Stockholm University's Department of Molecular Biology and Functional Genomics (2004-2007)
• Ramon y Cajal tenure-track contract recipient (2007)

Torrents Serra's research program centers on understanding the molecular mechanisms of bacterial infections, particularly focusing on ribonucleotide reductase regulation and biofilm formation. His laboratory investigates:

• Transcriptional regulation of bacterial ribonucleotide reductase genes
• Development of novel antimicrobial therapies targeting multidrug-resistant pathogens
• Host-pathogen interactions in polymicrobial infections
• Application of nanomedicine approaches for biofilm disruption
• Mechanisms of bacterial virulence in dual-species and polymicrobial communities

His publication record demonstrates a consistent focus on biofilm-related research, with particular emphasis on bacterial-fungal interactions and dual-species biofilm dynamics. Recent work increasingly incorporates nanotechnology approaches and advanced in vivo models like Galleria mellonella to bridge basic research with therapeutic applications. His group has made significant contributions to understanding priority effects in microbial colonization and the complex interactions between pathogens in co-infection scenarios.

As leader of an active research group at IBEC, Torrents Serra mentors numerous researchers and collaborates extensively across disciplines. His work has practical implications for developing new strategies against persistent biofilm-associated infections that challenge conventional antibiotic therapies.